> Denmark's Egalet, a drug delivery company focused on developing oral controlled-release products, has garnered a $27.6 million round of financing in a private placement led jointly by new investors Atlas Venture and Index Ventures. Release
> Cook Group has agreed to pay up to $100 million to license AVI BioPharma's Neugene antisense technology for developing new therapies for vascular diseases. Release
> Myriad Genetics has begun the largest drug trial to date for an Alzheimer's therapy. Researchers will test 1,600 patients in a trial of Flurizan. Article
> Alba Therapeutics announced the successful completion of Phase Ib proof-of-concept studies for its lead compound, AT1001. Release
> Merck has unveiled new data showing that Vytorin performed well in reducing the level of "bad" cholesterol. A new analysis of three studies led researchers to conclude that Vytorin had reduced LDL by 52.5 percent. Zocor produced an average reduction of 38 percent. Release
> Allergan has extended the expiration date for an exchange offer for all shares of Inamed. Release
> Columbia Laboratories will raise $30 million through a stock offering. Release
And Finally… A B-vitamin regimen demonstrated no efficacy in preventing heart attacks and strokes among high-risk patients. Article